Faron Pharmaceuticals Financials
| FARN Stock | 170.00 2.50 1.49% |
EPS Estimate Current Year (0.36) | Return On Equity (39.62) |
Faron | Select Account or Indicator |
Understanding current and past Faron Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Faron Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Faron Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Faron Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Faron Pharmaceuticals Oy. Check Faron Pharmaceuticals' Beneish M Score to see the likelihood of Faron Pharmaceuticals' management manipulating its earnings.
Faron Pharmaceuticals Stock Summary
Faron Pharmaceuticals competes with Samsung Electronics, Samsung Electronics, Hyundai, Toyota, and State Bank. Faron Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | FI4000153309 |
| Business Address | Joukahaisenkatu 6 B, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.faron.com |
| Phone | 358 2469 5151 |
You should never invest in Faron Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Faron Stock, because this is throwing your money away. Analyzing the key information contained in Faron Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Faron Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Faron Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Faron Pharmaceuticals reports annually and quarterly.| Gross Profit | 803 K | ||||
| EBITDA | (28.37 M) | ||||
| Net Income | (30.94 M) | ||||
| Total Asset | 10.22 M | ||||
| Retained Earnings | (172.21 M) |
Faron Pharmaceuticals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.2M | 8.4M | 13.2M | 11.3M | 10.2M | 10.5M | |
| Other Current Liab | 2.8M | 4.1M | 4.3M | 3.3M | 2.4M | 2.7M | |
| Net Debt | (4.2M) | (883K) | (3.3M) | 6.3M | 6.2M | 6.5M | |
| Retained Earnings | (80.0M) | (96.6M) | (116.3M) | (143.7M) | (172.2M) | (163.6M) | |
| Accounts Payable | 3.0M | 2.1M | 2.2M | 5.1M | 9.0M | 9.4M | |
| Long Term Debt | 2.3M | 2.7M | 2.9M | 11.1M | 9.4M | 9.9M | |
| Net Receivables | 1.3M | 1.3M | 1.4M | 905K | 1.0M | 981.9K | |
| Other Current Assets | 2.1M | 3.3M | 5.2M | 2.7M | 2.0M | 2.5M | |
| Total Liab | 8.6M | 10.2M | 10.3M | 22.7M | 25.4M | 26.7M | |
| Total Current Assets | 9.2M | 7.4M | 12.0M | 9.7M | 8.9M | 9.2M | |
| Intangible Assets | 529K | 565K | 899K | 1.2M | 1.1M | 691.5K | |
| Net Tangible Assets | 1.1M | (2.4M) | 2.0M | (12.6M) | (11.4M) | (10.8M) | |
| Short Long Term Debt | 163K | 122K | 429K | 1.9M | 3.5M | 3.6M | |
| Cash | 7.1M | 4.1M | 6.9M | 7.0M | 6.9M | 5.4M | |
| Net Invested Capital | 4.0M | 1.0M | 6.3M | 1.5M | (2.3M) | (2.1M) | |
| Net Working Capital | 3.1M | 868K | 4.8M | (741K) | (6.1M) | (5.8M) |
Faron Pharmaceuticals Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 224K | 389K | 235K | 1.4M | 2.2M | 2.3M | |
| Operating Income | (13.1M) | (16.7M) | (21.1M) | (27.4M) | (28.6M) | (27.1M) | |
| Ebit | (13.0M) | (16.8M) | (21.0M) | (27.4M) | (28.6M) | (27.1M) | |
| Research Development | 10.2M | 13.9M | 17.4M | 20.7M | 19.5M | 12.5M | |
| Ebitda | (12.8M) | (16.5M) | (20.7M) | (27.1M) | (28.4M) | (27.0M) | |
| Income Before Tax | (13.3M) | (16.9M) | (21.2M) | (28.7M) | (30.9M) | (29.4M) | |
| Net Income | (13.3M) | (16.9M) | (21.2M) | (30.0M) | (30.9M) | (29.4M) | |
| Income Tax Expense | 11K | 10K | 16K | 1.3M | 1.5M | 1.6M | |
| Tax Provision | 1K | 2K | 11K | 10K | 16K | 0.0 | |
| Net Interest Income | (158K) | (282K) | (245K) | (1.3M) | (2.4M) | (2.3M) | |
| Interest Income | 148K | 9K | 2K | 11K | 230K | 125K |
Faron Pharmaceuticals Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 3.0M | (3.0M) | 2.7M | 137K | (114K) | (108.3K) | |
| Free Cash Flow | (11.6M) | (17.6M) | (22.7M) | (23.4M) | (23.9M) | (22.7M) | |
| Depreciation | 238K | 283K | 307K | 300K | 346K | 198.9K | |
| Other Non Cash Items | 158K | (438K) | (1.2M) | (626K) | 1.1M | 1.2M | |
| Capital Expenditures | 100K | 142K | 474K | 385K | 123K | 243.7K | |
| Net Income | (13.3M) | (16.9M) | (21.2M) | (28.7M) | (30.9M) | (29.4M) | |
| Net Borrowings | 156K | 313K | 349K | 10.2M | 11.7M | 12.3M | |
| Change To Netincome | 164K | 56K | 430K | 671K | 771.7K | 399.3K | |
| End Period Cash Flow | 7.1M | 4.1M | 6.9M | 7.0M | 6.9M | 5.4M | |
| Investments | (100K) | (142K) | (473K) | (385K) | (123K) | (129.2K) |
Faron Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Faron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Faron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Faron Pharmaceuticals competition to find correlations between indicators driving Faron Pharmaceuticals's intrinsic value. More Info.Faron Pharmaceuticals Oy is rated # 4 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Faron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Faron Pharmaceuticals Systematic Risk
Faron Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Faron Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Faron Pharmaceuticals correlated with the market. If Beta is less than 0 Faron Pharmaceuticals generally moves in the opposite direction as compared to the market. If Faron Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Faron Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Faron Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Faron Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Faron Pharmaceuticals Oy Total Assets Over Time
Faron Pharmaceuticals December 16, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Faron Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Faron Pharmaceuticals Oy. We use our internally-developed statistical techniques to arrive at the intrinsic value of Faron Pharmaceuticals Oy based on widely used predictive technical indicators. In general, we focus on analyzing Faron Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Faron Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 19.89 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 6.94 |
Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.